AUPH:NSD-Aurinia Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 11.35

Change

0.00 (0.00)%

Market Cap

USD 1.45B

Volume

2.76M

Avg Analyst Target

USD 27.17 (+139.35%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-07-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

N/A

USD140.07B 233.80 177.21
BNTX BioNTech SE

N/A

USD68.10B 51.40 36.74
REGN Regeneron Pharmaceuticals, Inc

N/A

USD62.47B 16.69 13.11
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD51.90B 19.11 12.98
ALXN Alexion Pharmaceuticals, Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene, Ltd

N/A

USD29.28B N/A N/A
GMAB Genmab A/S

N/A

USD29.00B 33.07 3.64
SGEN Seagen Inc

N/A

USD26.42B 40.63 36.19
RPRX Royalty Pharma plc

N/A

USD24.49B 33.25 14.59
ALNY Alnylam Pharmaceuticals, Inc

N/A

USD21.44B N/A N/A

ETFs Containing AUPH

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -17.93% 42% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -17.93% 42% F 18% F
Trailing 12 Months  
Capital Gain -18.46% 42% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -18.46% 42% F 14% F
Trailing 5 Years  
Capital Gain 274.59% 85% B 86% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 274.59% 85% B 86% B
Average Annual (5 Year Horizon)  
Capital Gain 54.03% 77% C+ 86% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 54.03% 77% C+ 86% B
Risk Return Profile  
Volatility (Standard Deviation) 79.75% 38% F 21% F
Risk Adjusted Return 67.75% 91% A- 82% B-
Market Capitalization 1.45B 79% C+ 71% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 4.01 44% F 36% F
Price / Cash Flow Ratio -20.83 78% C+ 80% B-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -40.13% 65% D 32% F
Return on Invested Capital -28.59% 70% C- 24% F
Return on Assets -21.82% 54% F 16% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 4.32 43% F 28% F
Short Percent 10.44% 27% F 18% F
Beta 0.34 88% B+ 89% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector